Maryam Jafarpour

Maryam Jafarpour

Auto-generated profile, based on publicly available information

Maryam Jafarpour

Center for Medical Data Science, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in JMIR Cardio
Verified
Journal Article
Open access
FRFatemeh Sarani Rad
Fatemeh Sarani Rad
EBEhsan Bitaraf
Ehsan Bitaraf
MJMaryam Jafarpour
Maryam Jafarpour
JLJuan Li
Juan Li
Background: Digital twin systems are emerging as promising tools in precision cardiology, enabling dynamic, patient-specific simulations to support diagnosis, risk assessment, and treatment planning. However, the current landscape of cardiovascular digital twin development, validation, and implementation remains fragmented, with substantial variability in modeling approaches, data use, and reporting practices. Objective: This systematic review aims to synthesize the current state of cardiovascular digital twin research by addressing 11 research questions spanning modeling technologies, data infrastructure, clinical applications, clinical impact, implementation barriers, and ethical considerations. Methods: We systematically searched 5 databases (PubMed, Scopus, Web of Science, IEEE Xplore, and Google Scholar) and screened 330 records. Forty-two original studies met the predefined eligibility criteria and were included. Data extraction was guided by 11 thematic research questions. Mechanistic and artificial intelligence (AI) or machine learning (ML) modeling strategies, data modalities, visualization formats, clinical use cases, reported impacts, limitations, and ethical or legal issues were coded and summarized. Risk of bias was evaluated using a custom checklist for modeling studies, the Prediction Model Risk of Bias Assessment Tool (PROBAST) for prediction models, and the Risk of Bias in Non-Randomized Studies - of Interventions (ROBINS-I) for observational studies. Results: Most digital twins (29/42, 69%) relied on mechanistic models, while hybrid mechanistic–data-driven approaches and purely data-driven designs were less frequent (13/42, 31%). Only 18 studies explicitly described ML or AI, most often deep learning, Bayesian methods, or optimization algorithms. Personalization depended primarily on imaging (32/42, 76%) and electrocardiography or other electrical signals (18/42, 43%). Visualization was dominated (41/42, 98%) by static figures and anatomical snapshots. Clinically, digital twins were most commonly applied to therapy planning, risk prediction, and monitoring. Reported benefits focused on improved decision-making and therapy-related impacts, with occasional (8/42, 19%) reports of increased accuracy or faster diagnosis, but there was limited evidence for downstream improvements in patient outcomes. Key barriers included strong model assumptions and simplifications; high computational cost; data quality and availability constraints; limited external validation; and challenges in real-time performance, workflow integration, and usability. Explicit discussion of ethical, legal, or governance issues was rare (7/42, 17%). Conclusions: Cardiovascular digital twins show substantial potential to advance precision cardiology by linking personalized physiological models with clinical decision support, particularly for therapy planning and risk prediction in arrhythmia and heart failure. However, real-world implementation is constrained by methodological heterogeneity, restricted data and validation practices, limited openness of code and models, and sparse engagement with ethical and governance questions. Future research should prioritize standardized evaluation frameworks, robust clinical validation, interoperable and user-centered system design, and ethically grounded, patient-centered development to realize the full clinical value of digital twin systems.

1 January 2014
Verified
Journal Article
Closed access
HRHossein Riazi
Hossein Riazi
MJMaryam Jafarpour
Maryam Jafarpour
EBEhsan Bitaraf
Ehsan Bitaraf

11 April 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
ZMZhila Maghbooli
Zhila Maghbooli
ASArash H Shirvani
Arash H Shirvani
MJMaryam Jafarpour
Maryam Jafarpour
SNSima Noursaadat
Sima Noursaadat
MRMajid Ramezani
Majid Ramezani
SMSyamak Moattari
Syamak Moattari
Introduction It is estimated that Iran accounted for about 1% of hip fracture burden of the world in 2007, but these data are based on incomplete evidence. As the country’s population is ageing, it is expected that a dramatic rise in hip fracture incidence will result. There is no single national study that accurately estimates the incidence of all hip fractures in the country or identifies the direct costs for affected patients. To help fill this gap, the current study has been designed to determine the incidence of hip fracture associated with osteoporosis in the Iranian population and to assess the direct costs involved. Methods and analysis This is a cross-sectional analysis of 2 years of hospital admissions due to hip fracture in Iran from October 2014 to October 2016 using an electronic health record called SEPAS. SEPAS is a nationwide health information system established by Information Technology (IT) and the Statistics Department of the Ministry of Health. SEPAS has recorded more than 8.5 million inpatient hospitalizations since October 2014. Our study will identify reported hip fracture data in SEPAS among admitted adult hospital patients aged ≥50 in Iran. International Classification of Diseases ICD-9 and 10 will be used as diagnostic codes. Study factors are demographic data, types of fracture, types of treatment, duration of admission, early complications, in-hospital mortality and direct cost of fracture treatment. The accuracy of the SEPAS fracture data will be ascertained through a pilot study that compares the SEPAS data with the data directly extracted from medical records of the Shariati Hospital in Tehran during the study period. Ethics and dissemination The study protocol was approved by the Ethics Committee of the National Institute for Medical Research Development of Iran. Dissemination plans include academic publications, conference presentations and social media.

1 November 2017
Verified
Journal Article
Closed access
SMShahnaz Mojarrab
Shahnaz Mojarrab
ARAli Rafei
Ali Rafei
SAShahin Akhondzadeh
Shahin Akhondzadeh
AJAlireza Jeddian
Alireza Jeddian
MJMaryam Jafarpour
Maryam Jafarpour
KZKazem Zendehdel
Kazem Zendehdel

26 June 2025
Verified
Book Chapter
Open access
PDF file
MJMaryam Jafarpour
Maryam Jafarpour
AJAdnan Jouned
Adnan Jouned
LTLaura Sophia Tassatti
Laura Sophia Tassatti
FKFlorian Katsch
Florian Katsch
GDGeorg Duftschmid
Georg Duftschmid
Interoperability in healthcare information systems is crucial for seamless data exchange. Legacy systems often employ the Entity-Attribute-Value (EAV) model, which poses significant challenges for data standardization and integration with modern frameworks like HL7 Fast Healthcare Interoperability Resources (FHIR). This paper presents an easily reusable open-source implementation of a FHIR façade for EAV-based legacy health information systems based on HAPI FHIR. The proposed methodology separates the mapping logic from the implementation code, allowing for easier maintenance and updates. We demonstrate how this approach addresses key challenges in transforming legacy EAV data to FHIR resources, particularly focusing on the management of multiple source forms and the need for a maintainable solution. Initial results show that the approach is effective, achieving high accuracy in data transformation while maintaining system stability and ease of maintenance.

18 June 2026 in JMIR Diabetes
Verified
Journal Article
Open access
FRFatemeh Sarani Rad
Fatemeh Sarani Rad
MJMaryam Jafarpour
Maryam Jafarpour
EBEhsan Bitaraf
Ehsan Bitaraf
KKKatayoon Khaleghdadi
Katayoon Khaleghdadi
JLJuan Li
Juan Li
Background: Digital twin (DT) systems have emerged as a promising approach in health care, enabling real-time, patient-specific virtual modeling and personalized interventions. In diabetes care, DTs offer the potential to revolutionize glucose management, decision support, and therapy personalization through integration of real-time and longitudinal patient data. Objective: This scoping review mapped the current landscape of DT applications in diabetes and synthesized evidence across 13 research questions organized into 7 thematic domains: system design, target conditions, data sources, personalization strategies, intelligence and adaptability, validation methods, and implementation considerations. Methods: This scoping review was conducted in accordance with the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) and JBI methodological guidance for scoping reviews. A literature search was performed in PubMed, IEEE Xplore, Scopus, and Web of Science for studies published up to April 2025; all databases were last searched on June 23, 2025. Eligible studies were original empirical articles in English that described patient-specific DT systems or closely related individualized virtual models applied to diabetes diagnosis, monitoring, management, treatment, or complication-related care. Reviews, editorials, commentaries, theoretical papers without original data, and studies not focused on diabetes were excluded. Furthermore, FSR, MJ, and KK independently screened records and assessed full texts, with disagreements resolved through discussion and, when needed, by EB. Data were charted using a structured framework based on 13 predefined research questions, and were synthesized descriptively and thematically. Results: Of 208 records identified, 123 underwent title and abstract screening, 39 full texts were assessed for eligibility, and 28 studies were included. Most studies focused on type 1 or type 2 diabetes and used data-driven, hybrid, or simulation-based DT approaches. Common clinical applications included therapeutic control, glucose prediction, decision support, and disease management. Lifestyle data, wearables, continuous glucose monitoring, and electronic health records were the dominant inputs, while personalization relied on adaptive feedback, insulin optimization, and behavior-driven tools. Intelligent features, such as adaptive learning, explainable artificial intelligence, and real-time synchronization, enhanced adaptability, although human oversight was rare. Validation was mainly retrospective or simulation-based, with few clinical trials; reported outcomes included improved hemoglobin A 1c , time-in-range, and reduced hypoglycemia. Ethical discussions focused on data privacy, while implementation barriers centered on validation gaps, data quality, and workflow integration. Conclusions: DT research in diabetes is expanding and shows strong potential for personalized and data-driven care; however, the evidence base remains heterogeneous, inconsistently reported, and limited in prospective clinical validation. Key gaps include standardized definitions, robust real-world evaluation, fairness and governance considerations, and integration into clinical workflows. Future work should prioritize clinically grounded validation, regulatory readiness, and interoperable architectures to support safe, equitable, and scalable implementation.